Get the Stockscreener App
9.83
6.56%
-0.69
Puma Biotechnology Inc stock is traded at $9.83, with a volume of 406.59K.
It is down -6.56% in the last 24 hours and up +4.69% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$10.52
Open:
$10.51
24h Volume:
406.59K
Relative Volume:
1.21
Market Cap:
$507.43M
Revenue:
$227.18M
Net Income/Loss:
$24.38M
P/E Ratio:
20.59
EPS:
0.4774
Net Cash Flow:
$53.60M
1W Performance:
-4.47%
1M Performance:
+4.69%
6M Performance:
+35.77%
1Y Performance:
+81.70%
1-Day Range:
$9.81
$10.51
1-Week Range:
$9.81
$10.72
52-Week Range:
$4.575
$10.72
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
9.83 | 507.43M | 227.18M | 24.38M | 53.60M | 0.4774 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month - Zacks Investment Research
Puma Biotechnology grants shares. TD Cowen targets Puma Biotechnology stock at USD 6.00 - ad-hoc-news.de
Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
how InvestingPro’s fair value caught Puma Biotech’s 95% surge By Investing.com - Investing.com
Puma Biotechnology stock fell 1.76 percent after award news - AD HOC NEWS
Form 13D/A Puma Biotechnology For: 6 October By Investing.com - Investing.com Canada
Form 13D/A Puma Biotechnology For: 6 October By Investing.com - Investing.com UK
A CEO's $16-per-share warrant expired unexercised at Puma Biotechnology (PBYI). - Stock Titan
Alan H. Auerbach's 2.1M Puma Biotechnology Warrants Expire Without Exercise - Kalkine Media
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)October 5, 2026 - BioSpace
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Puma Biotechnology, Inc. (PBYI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates - Kalkine
Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates - kalkine.ca
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins - Yahoo Finance
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer - BioSpace
Puma Biotechnology initiates phase II lung cancer trial - Investing.com
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer - Yahoo Finance
About 50 patients with small cell lung cancer will join Puma's new trial. - Stock Titan
Puma Biotechnology director Troy Wilson sells $45,500 in stock - Investing.com
Puma Biotechnology (NASDAQ: PBYI) director exercises 50K options, sells 62K shares - Stock Titan
Puma Biotechnology (PBYI) Trades Essentially Flat at $9.26, Holding Above $8.80 SupportSweep Order Flow - careplusvn.com
Puma Biotechnology (PBYI) director lines up $45.5K stock sale - Stock Titan
Insider at Puma Biotechnology (NASDAQ: PBYI) files notice to sell shares - Stock Titan
Puma Biotechnology CEO Alan Auerbach presents at H.C. Wainwright Global Investment Conference - Bitget
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference - BioSpace
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference - Yahoo Finance
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? - Zacks Investment Research
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise (NASDAQ:PBYI) - Seeking Alpha
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - Eastern Progress
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 - biospace.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
InvestingPro’s fair value model spotted Puma Biotech’s 95% rally By Investing.com - Investing.com
Puma Biotechnology (PBYI) Pulls Back 1.93% to $9.14, Pressing Closer to Key SupportMcClellan Summation - vinanet.vn
Puma Biotechnology (PBYI) Pulls Back 1.93% to $9.14, Pressing Closer to Key SupportWeak Sell Signals - dars.gov.et
PBYI | PUMA BIOTECHNOLOGY INC FinancialsRevenue Breakdown - Quiver Quantitative
Puma (PBYI) Latest Quarter: The Available Earnings Metric Delivers a Beat; Investor Response: The Stock Ends Down 4.00% for the Current SessionEarnings Turnaround - vinanet.vn
Puma (PBYI) Latest Quarter: EPS Lands Above Forecast in the Current Update; Trading Move: Shares Move 4.76% Up in the Latest SessionEPS Growth Report - vinanet.vn
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - MarketBeat
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript - AOL.com
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? - Yahoo Finance
Puma Biotechnology, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-08-10 - Seeking Alpha
Puma Biotechnology Reports $56.5M Revenue and Profitability in Q2 - sekbernews.id
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades - Sahm
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Puma Biotech earnings beat by $0.16, revenue topped estimates - Investing.com Nigeria
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WILSON TROY EDWARD | Director |
Sep 14 '26 |
Proposed Sale |
9.10 |
5,000 |
45,500 |
0 |
| Cesano Alessandra | Director |
Sep 14 '26 |
Option Exercise |
2.93 |
50,000 |
146,500 |
118,850 |
| Cesano Alessandra | Director |
Sep 14 '26 |
Proposed Sale |
9.10 |
62,150 |
565,565 |
0 |
| Cesano Alessandra | Director |
Sep 14 '26 |
Sale |
9.12 |
62,150 |
566,994 |
56,700 |
| AUERBACH ALAN H | Officer |
Jul 06 '26 |
Proposed Sale |
8.26 |
44,058 |
364,042 |
0 |
| HUNT DOUGLAS M | Officer |
Jul 06 '26 |
Proposed Sale |
8.26 |
8,460 |
69,903 |
0 |
| NOUGUES MAXIMO F | Officer |
Jul 06 '26 |
Proposed Sale |
8.26 |
9,386 |
77,555 |
0 |
| AUERBACH ALAN H | President and CEO |
Jul 06 '26 |
Sale |
8.26 |
44,058 |
364,051 |
7,261,671 |
| HUNT DOUGLAS M | See Remarks |
Jul 06 '26 |
Sale |
8.26 |
8,460 |
69,905 |
196,841 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jul 06 '26 |
Sale |
8.26 |
9,386 |
77,557 |
230,637 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):